Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Blood (2024) 144 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2024-209389

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Anoop K Enjeti, Suthanthirakannan Ramamoorthy, Devendra Hiwase, Asma Ashraf, Belinda E Butcher, Sushma Kollipara, Carolyn S. Grove, Andrew H Wei, Jake Shortt

Blood (2024) 144 (Supplement 1): 4605.1.

https://doi.org/10.1182/blood-2024-202604

Published: 2024

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Blood (2024) 144 (Supplement 1): 303.

https://doi.org/10.1182/blood-2024-209378

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Blood (2024) 144 (Supplement 1): 217.

https://doi.org/10.1182/blood-2024-199882

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, Nirmal Robinson, Monika Kutyna, Kelly Lim, Chloe Thompson-Peach, Steven W Lane, David T Yeung, Agnes S. M. Yong, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2024-204177

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Blood (2024) 144 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2024-208841

Published: 2024

Journal Articles

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David T Yeung, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2024-212120

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Gauri Wechalekar, Alia Cibich, Monika Kutyna, Naranie Shanmuganathan, Usha Chandra Sekaran, Deepak Singhal, Ashanka Mahilal Beligaswatte, Leanne Purins, Christopher N. Hahn, David T Yeung, Peter Bardy, Duncan Purtill, Ashish Bajel, Susan Branford, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 4928.

https://doi.org/10.1182/blood-2024-209049

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Blood (2024) 144 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2024-208186

Published: 2024

Journal Articles

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Devendra Hiwase, Zoe Price, Chung How Kok, Monika Kutyna, Deepak Singhal, Naranie Shanmuganathan, Lesley Rawlings, David M Ross, David T Yeung, Anna Brown, Christopher N. Hahn, Lucy Godley, Caner Saygin, Hamish S Scott

Blood (2024) 144 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2024-211795

Published: 2024

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Extended Rhesus and Kell Phenotype-Matched Red Blood Cell (RBC) Transfusions Reduce RBC Alloimmunization and RBC Transfusion Burden in Patients with Myeloid Neoplasm

Michaela Spooner, Joanne Yu, Thomas Wiseman, Carla Toop, Shreyas Khanna, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2024-212000

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Extended Rhesus and Kell Phenotype-Matched Red Blood Cell (RBC) Transfusions Reduce RBC Alloimmunization and RBC Transfusion Burden in Patients with Myeloid Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only